Skip to main content

Table 3 Characteristics of the patients with liver biopsy depending on the histological liver lesions

From: Rare incidence of methotrexate-specific lesions in liver biopsy of patients with arthritis and elevated liver enzymes

  AIH-like lesions (n= 17) NASH-like lesions (n= 13) LL lesions (n= 7) PBC (n= 2) Direct MTX toxicity (n= 2) Pvalue
Sex (female/male) 13/4 8/5 5/2 2/0 0/2 NS
Age (years) 55.2 ± 3.2 51.2 ± 3.2 47.7 ± 4.5 57.5 ± 6.5 44.5 ± 1.5 NS
Disease duration (years) 10.5 ± 2.2 5.2 ± 1.1 4.6 ± 1.8 6.2 ± 1.8 6.9 ± 4.9 NS
MTX exposure (weeks) 139.9 ± 44.8 132.8 ± 33.8 26.1 ± 7.2 227.6 ± 158.2 325.7 ± 282.9 NS
MTX cumulative dose (mg) 1,260.9 ± 324.3 1,458.4 ± 460.9 306.1 ± 77 1,676.9 ± 1,156.9 3,454.2 ± 3,025.7 NS
MTX weekly dose (mg/week) 10.2 ± 1.7 12 ± 1.3 11.6 ± 1.6 7.4 ± 0.1 10.3 ± 0.3 NS
Patients on steroid 7/17 4/13 1/7 0/2 0/2 NS
Fibrosis 11/17 8/13 0/7 2/2 2/2 0.01
Shared epitope positivity 12/15 4/12 1/7 0/2 ND 0.01
HLA-B27 positivity 3/15 1/12 2/7 0/2 ND NS
HLA-DRB1*03 positivity 1/15 2/12 2/7 1/2 ND NS
Rheumatoid factor positivity 8/15 6/12 2/7 0/2 1/2 NS
Anti-CCP positivity 14/16 5/9 0/2 0/1 0/1 0.01
ANA positivity 10/16 4/13 2/7 2/2 1/2 NS
Anti-DNA antibody positivity 2/15 0/13 2/7 0/2 0/2 NS
Anti-SMA positivity 2/12 0/9 1/7 0/2 0/2 NS
Anti-LKM1, positivity 0/12 0/9 0/7 0/2 0/2 ND
AMA positivity 2/12 0/9 0/7 1/2 0/2 NS
  1. Data presented as n or mean ± standard error of the mean. AIH, autoimmune hepatitis; AMA, antimitochondrial antibodies; ANA, antinuclear antibodies; CCP, cyclic citrullinated peptide; LKM1, liver/kidney microsomal antibodies type 1; LL, limited liver; MTX, methotrexate; NASH, nonalcoholic steatohepatitis; ND, not determined; NS, not significant; PBC, primary biliary cirrhosis; SMA, smooth muscle antibodies.